Analysis of Dr. Reddy's corporate history, corporate relationships, biosimilars development pipeline, and Datamonitor's evaluation of the company's strategy and key strengths, weaknesses, opportunities and threats.
This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.
FEATURES AND BENEFITS
Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.
Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.
Dr.Reddy's has strategic aims to both expand the number of countries in which its four launched biosimilar products are marketed, as well as commercialize additional candidates - seven are in early development and pre-clinical testing.
YOUR KEY QUESTIONS ANSWERED
See how the success of the deal with Merck KGaA will be key to the company's long-run performance
Evaluate the copmany's experience in biosimilars development with 4 products launched in India and other RoW markets
Table of Contents
Table of Contents
ABOUT THIS REPORT
PharmaVitae Explorer database
Dr. Reddy's biosimilars overview
Dr. Reddy's biosimilars SWOT analysis
Dr. Reddy's biosimilars infrastructure
A fully integrated pharmaceutical generics player with focus on biosimilars
Dr. Reddy's adopts a competitive pricing strategy for its biosimilar brands
Dr. Reddy's biosimilar portfolio
Cresp (darbepoetin alfa)
Rituximab market size
Grafeel and Peg-grafeel (filgrastim and pegfilgrastim)
Filgrastim and pegfilgrastim market size
Deals and alliances
Table: Dr. Reddy's biosimilars development and marketing capabilities
Table: Dr. Reddy's biosimilar brands price comparison with reference brands, 2012
Table: Dr. Reddy's - biosimilar portfolio
Table: Forecast epoetin sales in the seven major markets ($m), 2011-16
Table: Forecast epoetin and darbepoetin sales in the seven major markets ($m), 2011-16
Table: Pipeline and marketed biosimilar epoetin drugs
Table: Forecasted rituximab sales in the seven major markets ($m), 2011-16
Table: Pipeline and marketed biosimilar rituximab drugs
Table: Forecasted filgrastim and pegfilgrastim sales in the seven major markets ($m), 2011-16
Table: Pipeline and marketed biosimilar filgrastim and pegfilgrastim drugs
Table: Dr. Reddy's global presence, 2012
Table: Dr. Reddy's deal activity and biosimilar deals, 2009-12
Table: Exchange rates, 2011
Figure: The PharmaVitae Explorer
Figure: Dr. Reddy's biosimilars overview
Figure: Dr. Reddy's biosimilars SWOT analysis
Figure: Dr.Reddy's revenues by segment, FY2007- FY2011
Figure: Dr. Reddy's biosimilars sales in India, FY2009-12
Figure: Reditux sales ($m), FY2008-11
Figure: Reditux vs other Dr. Reddy's biosimilar sales (%), 2009-11
Figure: Dr. Reddy's revenues, by geography ($m), 2005-11
Figure: Dr. Reddy's business divisions
Dr. Reddy's: Biosimilars Company Analysis published by Datamonitor in July 6, 2012. This report consists of Pages: 36 and the price starts from US $ 3800.